1  

ABOUT THE JOURNAL

The Journal of Sickle Cell Disease and Hemoglobinopathies (JSCDH), an official publication

of the Foundation for Sickle Cell Disease Research (FSCDR) publishes peer-reviewed

abstracts and articles of interest to clinicians, researchers, public health and health policy experts

in the field of sickle cell disease and hemoglobinopathies. The Journal’s scope is

multidisciplinary, representing all topics related to sickle cell disease and hemoglobinopathies.

Original state-of-the-art reviews, clinical studies, experimental investigations, new therapeutics,

case reports, editorials, articles on the business of sickle cell disease and hemoglobinopathies,

feature artciels and letters to the editor are published.

The Journal of Sickle Cell Disease and Hemoglobinopathies was established in 2013 as a

forum for all physicians, scientists, allied healthcare, public health professionals, pharmaceutical

and biotechnology researchers and developers, who are engaged or interested in sickle cell

disease and hemoglobinopathies. The Journal seeks to support sickle cell disease and

hemoglobinopathy specialists of all disciplines, improve patient care, and promote research and

development by publishing peer-reviewed materials related to the field of sickle cell disease and

hemoglobinopathies.

Online access to articles is restricted to subscribers and members of the Sickle Cell Research

Society of America (SCRSA) for a period of 2 years after publication, after which time the

materials are freely available to the public. In accordance with the National Institutes of Health

(NIH) Public Access Policy, any article supported by a grant from the NIH is immediately available

for access at PubMed Central. Funded open access to any article less than 2 years old is

available upon request. Articles published under “Current Issue” or “Available Issues” are the

version of record.

Author Instructions Abstracts and Manuscripts must address scientific hypothesis, significant

clinical observations, have public health impact, or contain primary data.

2  

Abstracts and Manuscripts submitted to the Journal of Sickle Cell Disease and

Hemoglobinopathy cannot be submitted to other meetings and/or published once submitted

JSCDH.

Fees There is a non-refundable handling fee for submitting an Abstract or Manuscript. There may

be additional fees for extra photos, graphs, tables, supplemental documents, special handling or

manipulation of graphics. Payment must be made by credit card; Visa, MasterCard, and

American Express are accepted. Purchase orders and checks will not be accepted.

Abstract for the Annual Meeting The abstract fee does not include registration for the annual

meeting; therefore, all authors planning to attend the FSCDR annual meeting must register for the

meeting.

Revisons No revisions can be made after the abstract submission deadline. The presentation at

the annual meeting must reflect the submitted abstract with the exception of updates on results

may be added.

Language Abstracts should be written in clear and concise English, so that reviewers are able to

focus solely on the scientific merits of the submission.